Regulatory Hearing Before the Food and Drug Administration; General Provisions; Amendments; Withdrawal
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Issuing agencies
Abstract
The Food and Drug Administration (FDA or Agency) published in the Federal Register of September 20, 2024, a direct final rule amending the Scope section of our regulation that provides for a regulatory hearing before the Agency. The comment period closed December 4, 2024. FDA is withdrawing the direct final rule because the Agency received significant adverse comment.
Full Text
<html>
<head>
<title>Federal Register, Volume 90 Issue 11 (Friday, January 17, 2025)</title>
</head>
<body><pre>
[Federal Register Volume 90, Number 11 (Friday, January 17, 2025)]
[Rules and Regulations]
[Page 5590]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2025-01145]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
21 CFR Part 16
[Docket No. FDA-2024-N-3654]
RIN 0910-AI97
Regulatory Hearing Before the Food and Drug Administration;
General Provisions; Amendments; Withdrawal
AGENCY: Food and Drug Administration, HHS.
ACTION: Direct final rule; withdrawal.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or Agency) published in
the Federal Register of September 20, 2024, a direct final rule
amending the Scope section of our regulation that provides for a
regulatory hearing before the Agency. The comment period closed
December 4, 2024. FDA is withdrawing the direct final rule because the
Agency received significant adverse comment.
DATES: The direct final rule published at September 20, 2024, 89 FR
77019, is withdrawn effective January 17, 2025.
FOR FURTHER INFORMATION CONTACT: Robert Schwartz, Center for Tobacco
Products, Food and Drug Administration, 10903 New Hampshire Ave.,
Silver Spring, MD 20993-0002, 1-877-287-1373,
<a href="/cdn-cgi/l/email-protection#93d0c7c3c1f6f4e6fff2e7fafcfde0d3f5f7f2bdfbfbe0bdf4fce5"><span class="__cf_email__" data-cfemail="8bc8dfdbd9eeecfee7eaffe2e4e5f8cbedefeaa5e3e3f8a5ece4fd">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION: Therefore, under the Federal Food, Drug, and
Cosmetic Act, and under authority delegated to the Commissioner of Food
and Drugs, the direct final rule published on September 20, 2024, 89 FR
77019 is withdrawn.
Dated: January 13, 2025.
P. Ritu Nalubola,
Associate Commissioner for Policy.
[FR Doc. 2025-01145 Filed 1-16-25; 8:45 am]
BILLING CODE 4164-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.